BIVI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIVI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioVie's interest expense for the three months ended in Sep. 2024 was $ -0.26 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.15 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioVie's Operating Income for the three months ended in Sep. 2024 was $ -4.12 Mil. BioVie's Interest Expense for the three months ended in Sep. 2024 was $ -0.26 Mil. BioVie did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for BioVie's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVie Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | -4.77 | -0.56 | -2.16 | -4.30 | -2.89 |
BioVie Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Interest Expense | Get a 7-Day Free Trial | -1.01 | -0.82 | -0.63 | -0.44 | -0.26 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVie (NAS:BIVI) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
BioVie's Interest Expense for the three months ended in Sep. 2024 was $-0.26 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-4.12 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $0.33 Mil.
BioVie's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as
BioVie did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Steve Gorlin | director | 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541 |
Cuong V Do | director | C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404 |
Richard J Berman | director | 305 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
James Paul Lang | director | C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404 |
Michael Edward Sherman | director | C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404 |
Robert J Hariri | director | 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924 |
Joanne Wendy Kim | officer: Chief Financial Officer | C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404 |
Joseph M Palumbo | other: Chief Medical Officer | 616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087 |
Jonathan M Adams | officer: EVP Liver Cirrhosis Programs | 100 CUMMINGS CENTER 247C, BEVERLY MA 01915 |
Penelope Markham | officer: EVP Liver Cirrhosis R&D | C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404 |
Christopher Reading | officer: EVP Neuroscience R&D | C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121 |
Clarence N. Ahlem | officer: EVP of Product Development | 5305 RENAISSANCE AVE., SAN DIEGO CA 92122 |
Mina Sooch | director | 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152 |
Sigmund Rogich | director | C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404 |
Patrick D Yeramian | officer: Chief Medical Officer | 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486 |
From GuruFocus
By Marketwired • 09-24-2024
By Marketwired • 09-23-2024
By Marketwired • 10-01-2024
By Marketwired • 08-13-2024
By Marketwired • 09-25-2024
By Marketwired • 10-22-2024
By Marketwired • 10-24-2024
By GlobeNewswire • 09-24-2024
By ACCESSWIRE • 10-11-2024
By Marketwired • 10-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.